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LE INFO ABSTRACT 
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Bisphosphonates are widely employed drugs for the treatrnent of pathologies characterized by excessive 
bone resorption, and display a great affinity for apatitic supports. ln this work we investigate how hydrox­
yapatite functionalization can influence the processes of adsorption and release of a bisphosphonate, 
namely risedronate. To this aim, pure hydroxyapatite (HA). hydroxyapatite with a partial substitution of 
Zn to Ca (ZnHA) and poly-ethylenimine-functionalized hydroxyapatite (HAPEI) were submitted to inter­
action with risedronate solution. The results indicate that the mechanisms of adsorption and release are 
greatly influenced by the type of the apatitic support. Ali the apatitic supports display Langmuir isotherms 
for risedronate adsorption. However in the case of HAPEI the plateau is not reached even at high equilib­
rium concentrations in solution. The data suggest that risedronate adsorption on HAPEI mineral-organic 
support occurs not only through chemisorption on apatitic phase, as on HA and ZnHA, but also through 
physisorption involved by PEI coating, which modulates also bisphosphonate release. These properties of 
tailor-made hydroxyapatite supports could be exploited to develop delivery systems for antiresorptive 
agents directly on osteoporotic sites. 
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ent of diseases associated to bone turn-over disorders 
 pathologies. such as osteoporosis, Paget's disease and 
astases [1,2). ln fact, these drugs not only display a great 
r the minerai phase of bone. preventing its dissolution. 
hibit osteoclast activity (3). However. their systemic pro­
e has been shown to provoke several negative side effects, 
 jaw osteonecrosis. gastrointestinal disorders. atypical 
nteric fractures (2.4.5). Moreover a low bioavailability is 
y observed for oral administration. Local release at spe­
 sites exhibiting a risk of fractures has been suggested as 
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bone substitute applications (6-13). BPs-functionalized 
 be prepared through adsorption from solution. as well 
ct synthesis in aqueous solution [9,12,13). A study car­
y Nancollas et al. using a constant composition method 
o determine the binding affinity of several BPs to hydrox­
HA) (14). Moreover. previous studies on the mechanism of 
n and desorption processes evidence the influence of the 
 and composition of the apatitic surface on the parameters 
tion of BPs and their kinetics of release [ 13, 15, 16). 
 study we investigated the role of composition and surface 
 hydroxyapatite supports on the adsorption and release 
ms of risedronate. To this aim, we utilized HA. HA with 
substitution of zinc to calcium (ZnHA). and HA func­
 with polyethyleneimine (HAPEI). PEI and Zn can indeed 
erent useful roles. PEI is a polycationic polymer contain­
 density of ionizable amino groups, widely employed to 
or chromatographie applications and complex transfec­
ms (17-19). Herein we synthesized hydroxyapatite in the 
 of PEI in solution in order to get functionalized HA crystals 
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tith an increased number of positive charges on their surface with
espect to pure HA. Enhancement of positive charge on the surface
f the HA nanocrystals, thanks to the presence of the polycationic
olymer, should promote the adsorption of negatively charged BPs
rom solution and control their release.
On the other hand, cationic substitution in HA can inﬂuence
rystal growth and increase the speciﬁc surface area which in turn
ontrols the adsorption ability [20]. Zinc can partially substitute
or calcium in the structure of HA and has been demonstrated to
nhibit osteoclast formation and bone resorption [20,21]. Its pres-
nce into HA structure might inﬂuence BPs interaction with the
alcium phosphate surface. Moreover its co-presence with BPs in
A crystals should enhance the antiresorptive properties of the
aterial.
In the present paper, we investigated the interaction between
isedronate and different apatitic crystals (HA, HAPEI and ZnHA),
hrough the study of the adsorption reaction of this BP on these
ifferent apatitic supports and physicochemical characterization
f the solid products and of the supernatant solutions. Then, the
elease of risedronate from the three types of apatitic supports will
e studied and discussed.
. Materials and methods
.1. Synthesis of the apatitic samples
The synthesis of HA was carried out in N2 atmosphere using
O2 free water [22]. 50mL of a 1.08M Ca(NO3)2·4H2O solution
pH adjusted to 10 with NH4OH) was heated at 90 ◦C and 50mL of
.65M (NH4)2HPO4 solution was added drop-wise under stirring.
he precipitate was maintained in contact with the reaction solu-
ion for 5h at 90 ◦C under stirring, then centrifuged at 10,000 rpm
or 10min and repeatedly washed with CO2-free distilled water.
he product was dried at 37 ◦C overnight.
Hydroxyapatite at different poly(ethylenimine) contents
HAPEI) was obtained following the same experimental procedure
s for HA except that PEIwas added to the Ca(NO3)2·4H2O solution,
efore adjusting the pH to 10 with NH4OH. Poly(ethylenimine)
olution (Aldrich, MW∼2000gmol−1) was used. Concentrations
f PEI tested were 1, 2 and 4M (calculated with respect to the ﬁnal
olume of the precipitating medium) leading to HAPEI 1, HAPEI 2
nd HAPEI 4 samples, respectively.
Zn-substituted hydroxyapatite (ZnHA) was synthesized follow-
ng the same experimental procedure as for HA, but the cationic
olution was prepared by dissolving the appropriate amounts of
a(NO3)2·4H2O and Zn(NO3)2·6H2O in CO2-free deionized water
efore adjusting the pH to 10 with NH4OH. The total cationic con-
entration was 1.08M, and the Zn/(Ca +Zn) molar ratio was 0.1.
.2. Risedronate adsorption and release
Adsorption experiments were carried out on HA, ZnHA and
APEI. The HAPEI samples used for risedronate adsorption study
as HAPEI 4, from now onwards indicated as HAPEI for sim-
licity. 50mg of apatitic sample were dispersed at physiological
emperature (37±1 ◦C) in 5mL of risedronate (Aldrich) solutions
concentration ranging from 0 to 3mM) in a polyethylene tube.
he latter were prepared by dissolving the appropriate amount
f risedronate in an aqueous 1mM KCl solution (standard solu-
ion); the pH of the obtained solutions was adjusted to 7.4 using
Cl or KOH solutions. After sonication for 1min, the suspen-
ions were incubated for 1h without stirring and then centrifuged
or 10min at 5000 rpm leading to the various BP-functionalized
patites: HABP, HAPEIBP and ZnHABP samples. This equilibration
ime (1h) was previously determined from kinetic experimentsusing a risedronate solution of 0.86mM; this time allowed to reach
the equilibrium of adsorption while minimizing the dissolution of
apatitic supports. Blanks containing only apatite incubated in KCl
solutions were used as controls. After centrifugation, the solids
obtained were washed with deionized water and dried at 37 ◦C
overnight. The supernatants were immediately ﬁltrated on 0.2m
Millipore ﬁlters and then stored at 4 ◦C before titration.
The risedronate concentration in the ﬁltrates was determined
using UV spectrophotometric absorption at 262nm (Hewlett
Packard 8452A diode array spectrophotometer). This wavelength
corresponds to the maximum absorbance of the pyridine group of
risedronate molecule.
Risedronate release proﬁles were obtained with a ﬂowthrough
cell system (USP Apparatus 4 Sotax CE6, Sotax AG, Switzerland)
with 12mm cells for powders and a peristaltic pump. In all exper-
iments, laminar ﬂow was used with one glass beads layer covered
with eachBP-functionalizedapatitic sample,mixedwith2gof glass
beads. Different weights were utilized for the analysis of the differ-
ent materials so that all the samples contained the same amount
of adsorbed BP (about 1.8mol/m2). The release tests were carried
out at 37.0±0.5 ◦C under sink conditions according to European
Pharmacopeia guidelines. Thedissolutionmediumusedwasdeion-
ized water pumped through the column at a ﬂow rate of 9mL/min.
A closed system was used, recycling 50mL of dissolution medium.
Fractions of 5mL were collected periodically and risedronate con-
tent was determined by UV spectrophotometry at 262nm. The
same volume of dissolution medium was replaced back after each
sampling in order to maintain the volume constant and sink con-
ditions. Release study was performed in triplicate for each type of
BP-functionalized apatite.
2.3. Sample characterization
X-Ray diffraction analysis was carried out by means of a PAN-
alytical X’Pert PRO powder diffractometer equipped with a fast
X’Celerator detector. Ni-ﬁltered CuK radiation was used (40mA,
40kV). The 2 range was investigated from 10◦ to 120◦ with a step
size of 0.033◦ and a time/step of 200 s. The determination of the cell
and size/strain parameters was obtained by a full proﬁle pattern
reﬁnement using the MAUD (Material Analysis Using Diffraction)
routine [23] with the Popa anisotropic size-strain model [24]. The
instrumental broadening was estimated by scanning the silicon
NIST 640e sample.
Ca, Zn and P contents in the solid products were determined by
means of an inductively coupled plasma (ICP) mass spectrometer
(ICP-AES, Horiba Jobin Yvon). Powders were previously dissolved
in 0.6M HNO3 solution.
The infrared spectrum of each synthesized and functionalized
apatite powder was recorded over the 400–4000 cm−1 range in
transmission mode with KBr pellets (2mg sample/300mg KBr)
using a Thermo Nicolet 5700 Fourier-transform infrared (FTIR)
spectrometer.
Raman spectra of the samples were generated on a Horiba,
Jobin-Yvon Labram HR800 confocal microspectrometer, equipped
with a helium–neon laser (=632.82nm). The spectral resolution
was2 cm−1, the laser powerwas2mWand integration times varied
from30 to 120 s. All spectrawere recordedover awavelength range
of 100–4000 cm−1. Three spectral accumulations were averaged.
For TEM investigations, a drop of sonicated apatitic calcium
phosphate suspension in ethanol was transferred onto holey car-
bon foils supported on conventional copper microgrids. A Philips
CM100 transmission electron microscope, operating at 80kV was
used.
Thermogravimetric analysis was carried out using a
PerkinElmer TGA-7. Heating was performed in a platinum
crucible in air ﬂow (20 cm3/min) at a rate of 10 ◦C/min up to 800 ◦C.
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aig. 1. Powder X-ray diffraction patterns and TEM images of the different synthesi
irect comparison.
he sample weights were in the range 5–10mg. Results from this
nalysis represent the mean value of determinations for three
ifferent samples of each composition.
Zeta potential wasmeasured using aMalvern Instruments Zeta-
izer Nano. 5mg of powder sample was suspended in 50mL of
illiQ water after sonication for 2min. Each analysis was per-
ormed in triplicate.
The speciﬁc surface areawasmeasuredusing aCarlo Erba Sorpty
750 BET analyzer using constant volume N2 adsorption with des-
rption at 80 ◦C.
. Results and discussion
.1. Characterization of the apatitic substrates
Chemical analysis of HA powder gave a Ca/P ratio of 1.67 char-
cteristic of stoichiometric hydroxyapatite (Table S1). The powder
RD patterns of HA, HAPEI (PEI concentration in solution: 4M) and
nHA are presented in Fig. 1.
It is evident that all the samples are constituted of apatitic
alcium phosphate as unique crystalline phase. However, the
roadening of the XRD peaks varies with the type of apatite sub-
trates synthesized. In particular, the reﬂections in the pattern of
APEI are more sharp than those of pure hydroxyapatite. We can
bserve that the products obtained through the synthesis of HA in
he presence of different PEI concentrations in solution, namely 1,
and 4M, display an increase of the sharpness of the diffraction
eaks on increasing PEI concentration (Fig. S1), which suggests an
ncrease of crystallinity of the apatites precipitated in these condi-
ions. This trend is conﬁrmed by the Raman spectroscopic analysis
f these samples (Fig. S2); indeed, the sharpness of the phosphates
able 1
attice parameters, coherent lengths (hkl) of the perfect crystalline domains in the direct
nd Zn content of the different apatitic samples synthesized (HA, HAPEI and ZnHA).
a (Å) c (Å) L 002 (Å) L 310 (Å) PEI con
HA 9.4378(3) 6.8862(2) 657(4) 311(3) –
HAPEI 9.4298(2) 6.8872(2) 929(7) 543(5) 2.4
ZnHA 9.4241(9) 6.8696(2) 367(4) 148(3) –atitic samples: HA, HAPEI, ZnHA. Magniﬁcation in all TEM images is the same for
and hydroxyl vibration bands characteristic of HA increases on
increasing PEI content. Moreover, the spectra of the samples con-
taining the cationic polymer exhibit the presence of two absorption
bands around 2800–2900 cm−1 characteristic of CH symmetric
and asymmetric stretching bands ( NH stretching vibration band
of PEI at about 3300 cm−1 cannot be observed probably due to their
low intensity) [25].
The lengths of the coherent domains (hkl) and the values of
microstrain () were calculated from the microstructure param-
eters determined from the X-ray diffraction pattern reﬁnement
procedure. The results show that the main contribution to the
broadening of the reﬂections is due to coherent length of the per-
fect crystalline domains, which increases signiﬁcantly both along
the c-axis direction and, even more, along the orthogonal direction
on increasing PEI content in the solids (Table S1). At variance, the
values of microstrain are of the order of 10−4 and do not change
appreciably as a function of composition. In agreement with the
increase of crystallinity, the lattice parameters exhibit a slight but
signiﬁcant reduction of the a-parameter on increasing PEI content
[26]. PEI content, determined through thermogravimetric analy-
sis (Fig. S3) increases as a function of concentration in solution
up to about 2.5wt.%. The hypothesis of an electrostatic interaction
between the polymer chain (rich in amino groups) and the surface
of the apatitic crystals is supported by the values of zeta poten-
tial, which assume positive values and increase on increasing the
content of the polycationic polymer (Table S1). The presence of PEI
associated with apatite nanocrystals inﬂuences their morphology:
when compared with HA nanocrystals, the HAPEI ones display a
shorter mean length and a greater thickness (Fig. 1).
However, the morphological variation does not provoke signiﬁ-
cantmodiﬁcation of the speciﬁc surface area, which is quite similar
ion normal to 002 and to 310 planes; Speciﬁc surface area (SSA); Zeta potential; PEI
tent (wt.%) Zn content (at.%) SSA (m2/g) Zeta potential (mV)
– 23 −15.6
– 26 +26.2
7.9 86 −15.3
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Table 2
Adsorption parameters of risedronate on HA, ZnHA and HAPEI samples, i.e. maxi-
mum amount at saturation (N) and apparent afﬁnity constant (K) calculated from
Langmuir equation plots.
N±N (mol/m2) K±K (Lmmo1−1)
HA 1.88±0.05 21±3ig. 2. Adsorption isotherms of risedronate on hydroxyapatite (HA), Zn-substituted
ydroxyapatite (ZnHA) and PEI-modiﬁed hydroxyapatite (HAPEI) at pH 7.4 and
7 ◦C. The data ﬁt the Langmuir isotherm.
o that of pureHA (Table 1). On thebasis of their increased thickness
nd coherent length of perfect crystalline domains, it could be sug-
ested that HAPEI nanocrystals can be considered as mesocrystals
27] made up of HA nanoparticles aligned by PEI: PEI could inter-
ct preferentially with the hydroxyapatite crystal faces parallel to
he c-axis and promote the oriented attachment of nanoparticles,
eading to the observed increased thickness (Table 1).
ZnHA nanocrystals exhibit more perturbed shape, ill-deﬁned
dges and signiﬁcantly reduced dimensions in comparison to HA
Fig. 1). Moreover, ZnHA displays a remarkably higher speciﬁc sur-
ace area when compared to HA and HAPEI, in agreement with
ts smaller crystal dimensions (Table 1). Zn inhibition of HA crys-
al growth is in agreement with previous studies [28,29] and it is
upported by the observed broadening of the diffraction peaks of
nHA with respect to those of HA (Fig. 1). Accordingly, the coher-
nt lengths of the perfect crystalline domains of ZnHA evaluated
rom the line broadening of the (002) and (310) are signiﬁcantly
educed with respect to those of pure HA (Table 1). Zn incorpora-
ion into HA crystals to about 7.9 atom.% provokes a reduction of
he lattice parameters, in agreement with its smaller ionic radius
ith respect to that of calcium [30], with no secondary crystalline
hase observed.
.2. Risedronate adsorption
The evolution of the amount of risedronate adsorbed on the
olids Qads (mol/m2) from the dilute solutions as a function of
he equilibrium BP concentration Ceq (0–2mM) is plotted in Fig. 2.
The isotherms obtained for HA and ZnHA are Langmuirian in
hape (r2 =0.87 and 0.94, respectively) and reached the plateau
t relatively low equilibrium concentrations (below 1mM), indi-
ating a high afﬁnity of risedronate for these apatitic surfaces.
imilar observations have been reported previously for the adsorp-
ion of bisphosphonate molecules (risedronate and tiludronate) on
patitic support [13,15,16]. For same weight of apatitic powders,
he risedronate content at plateau in presence of ZnHA was twice
s much as that adsorbed on HA (about 40 and 100mol/g for
A and ZnHA, respectively) mainly due to the higher speciﬁc sur-
ace area of ZnHA (86m2/g) compared with that of HA (23m2/g),
Table 1). The uptake of risedronate depended linearly on the
mount of released phosphate ions in solution (Fig. S4). Thereby,
he uptake of risedronate is proportional to the amount of phos-
hate ions released in solution indicating that the adsorption of
isedronate on HA affects the amount of ionic species in solution
nd can be described as a chemisorption corresponding to an ionZnHA 1.20±0.08 7±1
HAPEI 7.9±0.4 2.2±0.3
exchange process between bisphosphonate molecules in solution
and phosphates species on HA and ZnHA, as previously published
for bisphosphonates adsorption on apatitic surfaces [13–16,31].
The slope of the curve is close to 1 for HA and it increases for ZnHA.
Indeed thenumberof phosphate groups releasedper adsorbed rise-
dronate molecule varies as a function of the characteristics of the
apatitic support, as observed in previous studies on BPs adsorption
on apatitic substrates [15,16,31]. It can be noticed that the calcium
and zinc concentrations in the supernatants after adsorption were
low and not affected by the adsorption of risedronate (Ca concen-
trations forHAandHAPEI: below0.5mM;Zn andCa concentrations
for ZnHA: below 0.5mM and 2mM, respectively). These concen-
trations are related to slight dissolution of the supports during
adsorption experiments [16].
The parameters of adsorption can be determined from the Lang-
muir Eq. (1), (Table 2):
Qads = KNCeq/
(
1 + KCeq
)
(1)
where N corresponds to the maximum amount of adsorbed
risedronate (mol/m2) and K is the afﬁnity constant of rise-
dronate for the solid surface (L/mmol). The values of N obtained
for the HA and ZnHA supports are close (Table 2): 1.88±0.05 and
1.20±0.08mol/m2, respectively, and correspond to the values
previously obtained for the adsorption of risedronate molecules on
apatitic surface [13]. At the same time, a signiﬁcant decrease of the
afﬁnity K is observed for ZnHA (7±1L/mmol) compared with HA
(21±3L/mmol), (Table 2), possibly related to changes in surface
chemical composition.
The isotherm of risedronate adsorption on HAPEI can also be
described by the Langmuir model (r2 = 0.99). The amount adsorbed
at saturation, N, was higher on HAPEI (7.9±0.4mol/m2) than
on HA and ZnHA but the curve does not reach a plateau even at
high equilibrium concentrations in solution (Ceq). This can be due
to the competition of several processes: a chemisorption process
on HA surface and a physisorption process on PEI coating. The
decrease of the afﬁnity K for HAPEI (2.2±0.3 L/mmol), (Table 2)
can be explained by the presence of PEI on the apatitic surface. The
evolution of the amount of risedronate adsorbed as a function of
phosphate released in solution is still linear, but the slope appears
lower than for HA. The ion exchange process proposed to occur at
the surfaceof theapatite seems tobeaffectedby thepresenceof PEI.
The number of phosphate groups released per BPmolecule is lower
in the presence of PEI, in agreementwith the presence of twodiffer-
ent mechanisms of adsorption: risedronate chemisorption, which
provokes phosphate release, and risedronate physisorption, which
does not imply ion exchange.
3.3. Characterization of the solids after risedronate uptake
The results of XRD analysis of the solid products obtained after
bisphosphonate adsorption show that the presence of risedronate
does not inﬂuence the crystallinity of the apatitic samples and does
not provoke precipitation of any other crystalline phase (Fig. S5).
Similarly, TEM images of HABP, ZnHABP and HAPEIBP show
that the characteristic morphologies of the different apatitic sam-
ples used as substrates for risedronate adsorption are maintained
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1ig. 3. Raman spectra of risedronate sodium salt, HA, HABP and ZnHABP after
dsorption (with Qads equal to the maximum value of the adsorption isotherm).
fter adsorption, as it can be appreciated by comparing the images
eported in Fig. S6 with those in Fig. 1. Adsorption of BP does not
igniﬁcantly modify the values of zeta potential of HA and ZnHA,
hereas it provokes a slight, but appreciable, decrease of the zeta
otential of HAPEI (from 26.2 to 23.5mV).
Raman spectra of HA and ZnHA after adsorption (Fig. 3) show
he characteristic vibration bands of the apatitic structure [32],
specially those of apatitic phosphate groups: 2 (438–463 cm−1),
4 (580–614 cm−1), 1 (960 cm−1), 3 (1029–1077 cm−1), and the
H vibration band at 3560 cm−1 [33]. All spectra display addi-
ional bands which can be attributed to the presence of adsorbed
P: in particular, two bands between 2900 and 3000 cm−1, cor-
esponding to C H stretching, and two intense bands between
025 and 1055 cm−1 which might be assigned to C H pyridine
ing deformation, are present.Moreover, the spectra showmedium
ntensity bands between 1500 and 1600 cm−1, associated with the
ubstituted pyridine ring, and the characteristic Raman bands of
hosphonate groups between 850 and 1230 cm−1. Interestingly,
e can see that these bands are shifted compared to those of
isedronate sodium salt spectrum, showing a change in the envi-
ig. 5. (a) Risedronate (BP) released (wt.%) from the different apatitic samples as a fun
.8mol/m2. (b) Linear regression of Higuchi model (% BP released=KH ×√t, with KH conFig. 4. Raman spectra of risedronate sodium salt, PEI, HAPEI and HAPEIBP after
adsorption (with Qads equal to the maximum value of the adsorption isotherm).
ronment of these groups after adsorption. These spectroscopic
observations suggest a strong interaction between risedronate
molecule and calcium ions at the surface of the apatitic samples
after adsorption, as no insoluble calcium salts were observed by
XRD and TEM (Figs. S5 and S6). These results are in accordance
with the Langmuir model proposed for the adsorption isotherm,
and the mechanism of interaction based on ion exchange process.
A shift of the characteristic bands of risedronate is also observed
in the Raman spectrum of HAPEIBP after adsorption (Fig. 4), which
conﬁrmed that the process of adsorption of BP on the mineral part
of HAPEIwas similar.Moreover the presence of the vibration bands
of PEImolecules (especially stretching vibrations of CH, CH2 groups
between 2800 and 3000 cm−1) on HAPEIBP conﬁrmed that PEI was
still on HA surface after adsorption experiments. Thus, PEI is able
to participate to the process of BP adsorption.
3.4. Risedronate release
The results of kinetics of risedronate release from the different
apatitic supports are presented in Fig. 5a. The release was fast dur-
ing the ﬁrst hour and then slowed down, as observed in previous
studies for several apatitic supports [16]. All the samples release
a quantity of risedronate that represents a small percentage of the
initial adsorbed amount. However, the type of apatitic support is an
importantparameter forBP release control. In fact, the total amount
of risedronate released was higher from HAPEI (about 14% of the
initial quantity adsorbed) than from HA and ZnHA (about 5 and 9%
respectively) probably due to different processes of release.
In order to describe and correlate the mechanism of BP release
fromeach support, various usualmathematicalmodelswere tested
ction of time. The initial amount of BP on each sample was the same, i.e. about
stant) for the release kinetics of risedronate from HA, ZnHA and HAPEI.
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[34]. The results of curve ﬁtting with these models give interesting
ndicationson the releasebehaviorof risedronate fromthedifferent
ested supports.
First, the release of risedronate from the apatite supports with-
ut PEI (HA and ZnHA) cannot be directly described by a simple
iguchi diffusion model (r2 = 0.66 and 0.83 for HA and ZnHA,
espectively, Fig. 5b), suggesting another mechanism involving
ainly dissolution of the apatitic support [34]. In the case of HA
nd ZnHA, risedronate molecules were only slowly released from
hese apatitic supports because they were irreversibly bound by
hemisorption. Indeed the exchanged species cannot be removed
rom apatitic surface by simple dilution of the exchange solution or
imple washing of the solids, as previously published for adsorbed
olecules on apatites, particularly bisphosphonates [16]. There-
ore the release rate was limited by support dissolution keeping in
ind the diminishing surface of the apatitic particles during disso-
ution; the dissolution deceleration may be explained on the basis
f the reduction in particle size and surface as observed by sev-
ral authors for degradation kinetic studies of calcium phosphates
35,36].Moreover, assuming that the rate of dissolutiondepends on
he surface area of the particle, the higher BP release rate observed
rom ZnHA compared with HA can be attributed to its higher spe-
iﬁc surface area and solubility.
In contrast, the release mechanism from HAPEI seemed gov-
rned by simple laws of diffusion (r2 =0.98 from HAPEI, Fig. 5b)
s generally observed from polymeric matrix [34,37]. Liquid pen-
trates the PEI surface and dissolves the trapped drug, which then
iffuses into the release medium. However, if a total delivery of
he drugs may be obtained for pure diffusion model applied to
ure polymeric supports, it was not observed from HAPEI mineral-
rganic support (no more than 15% of the initial quantity adsorbed
re released after 7h of test) suggesting the involvement of a sec-
ndary mechanism related to the composite nature of the HAPEI.
he fast release observed during the ﬁrst hour can be attributed to
he release of the drug molecules associated to the organic phase
y physisorption, whereas the following slow release of BP can
e ascribed to dissolution of the apatitic phase. This more com-
lex mechanism of release explains the relatively higher quantity
f drug delivered from HAPEI compared with those from HA and
nHA.
. Conclusions
The results of this study indicate that all the apatitic sup-
orts display Langmuir isotherms of adsorption. The mechanism
f adsorption can be explained by ionic exchange between bispho-
phonate molecules in solution and phosphate on the surface of
patitic supports. The values of the parameters of adsorption, N and
, obtained for the HA and ZnHA supports are close and correspond
o the values previously obtained for the adsorption of risedronate
olecules on apatitic surfaces.
Interestingly, in the case of HAPEI, the plateau of the Lang-
uir isotherm of risedronate adsorption was not reached even at
igh equilibrium concentrations in solution. Risedronate adsorp-
ion on HAPEI mineral-organic support occurs not only through
hemisorption on apatitic phase, as for HA and ZnHA crystals,
ut also through physisorption involving PEI coating. Both mech-
nisms modulate bisphosphonate release. These results show that
imilarly to the adsorption process, risedronate release is directly
elated to the nature and the physicochemical characteristics of
he apatitic supports. The characteristics and properties of these
ailor-made hydroxyapatite supports could be exploited to develop
elivery systems for antiresorptive agents directly on osteoporotic
ites, allowing reduction of systemic treatments and associated
rawbacks.
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Figure S1. Powder X-ray diffraction patterns of the apatitic samples synthesized in the presence of 
different PEI concentrations in solution (HAPEI 1, HAPEI 2 and HAPEI 4 for 1 M, 2 M and 4 M of 
PEI in solution, respectively), compared with HA (without PEI) XRD pattern. 
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Figure S2. Raman spectra of the apatitic samples synthesized with different PEI concentrations in 
solution (HAPEI 1, HAPEI 2 and HAPEI 4 for 1 M, 2 M and 4 M of PEI in solution, respectively), 
compared with HA spectrum. 
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Figure S3. Thermogravimetric plots of the apatitic samples synthesized in the presence of different 
PEI concentrations in solution (HAPEI 1, HAPEI 2 and HAPEI 4 for 1 M, 2 M and 4 M of PEI in 
solution, respectively), compared with HA sample (without PEI).  
 
 
Figure S4. Concentration of phosphate ions in supernatants after adsorption of risedronate on HA, 
ZnHA and HAPEI. 
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Figure S5. XRD patterns of apatitic samples before (black) and after (red) the adsorption process (in 
risedronate solution at 3 mM). No difference can be appreciated before and after the adsorption 
process, as it can be seen also in the insets, where the order of plotting has been reversed in order to 
highlight possible dissimilarity. 
 
 
5 
 
 
 
 
Figure S6. TEM images of the different apatite samples obtained after risedronate adsorption. 
Magnification is the same in all the images for direct comparison. 
 
 
Table S1. Lattice parameters, coherent lengths (Lhkl) of the perfect crystalline domains and 
microstrain ( hkl ) in the direction normal to 002 and to 310 planes; PEI content, zeta potential and 
Ca/P molar ratio of the apatitic samples synthesized in the presence of different PEI concentrations 
in solution (HAPEI 1, HAPEI 2 and HAPEI 4 for 1 M, 2 M and 4 M of PEI in solution, respectively), 
compared with HA sample (without PEI). 
 HA HAPEI 1 HAPEI 2 HAPEI 4 
a (Å) 9.4318(3) 9.4358(2) 9.4299(2) 9.4298(2) 
c (Å) 6.8862(2) 6.8903(3) 6.8855(2) 6.8872(2) 
L002 (Å) 657(4) 667(5) 749(6) 929(7) 
L310 (Å) 311(3) 358(3) 405(4) 543(5) 
ε 002 (*10-4) 9.9(8.5) 6.9(5.1) 6.9(2.7) 5.9(7.0) 
ε 310 (*10-4) 6.0(1.2) 4.6(1.2) 6.2(2.3) 6.8(4.8) 
PEI content  
(wt%) 
--- 0.9(0.5) 1.7(0.5) 2.4(0.5) 
zeta potential (mV) - 15.6 + 19.5 + 24.2 + 26.2 
Ca/P 1.67 1.67 1.67 1.73 
 
